Maricann Group (CNSX:MARI – Get Free Report) had its price target raised by research analysts at Raymond James from $6.00 to $6.50 in a research note issued to investors on Tuesday, BayStreet.CA reports.
Separately, Canaccord Genuity Group decreased their price target on Maricann Group from $6.50 to $6.00 and set a “speculative buy” rating for the company in a report on Friday, January 12th.
View Our Latest Report on MARI
Maricann Group Price Performance
About Maricann Group
Maricann Group Inc, formerly Danbel Industries Corporation, is a Canada-based integrated producer and distributor of marijuana for medical purposes. As one of approximately 43 companies with a federal license to cultivate cannabis and one of approximately 30 independent licensed producers with a federal license to process and distribute cannabis, the Company’s services a patient base with more than 8,000 registered patients.
Recommended Stories
- Five stocks we like better than Maricann Group
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Charles Schwab Fortifies its Uptrend on EPS Beat
- What is the Nikkei 225 index?
- Lockheed Martin Stock Aims for a Fresh All-Time High
- Basic Materials Stocks Investing
- Beyond the Halving: The Future of Bitcoin Mining Stocks
Receive News & Ratings for Maricann Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maricann Group and related companies with MarketBeat.com's FREE daily email newsletter.
